Cancer Cachexia and Chronic Inflammation: an Unbreakable Bond

Overview

Journal Br J Cancer

Specialty Oncology

Date 2023 Feb 22

PMID 36807335

Authors

Antonio Maccio

Clelia Madeddu

Eleonora Lai

Mario Scartozzi

Affiliations

Soon will be listed here.

Citing Articles

Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors.

Madeddu C, Gramignano G, Lai E, Pinna G, Tanca L, Cherchi M ESMO Open. 2024; 9(10):103738.

PMID: 39389003 PMC: 11693429. DOI: 10.1016/j.esmoop.2024.103738.

The impact of diabetes, hypercholesterolemia, and low-density lipoprotein (LDL) on the survival of cervical cancer patients.

Qiu Q, Song J, Zheng X, Zheng H, Yi H Discov Oncol. 2024; 15(1):349.

PMID: 39143292 PMC: 11324628. DOI: 10.1007/s12672-024-01224-5.

Defining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.

Park M, Whelan C, Ahmed S, Boeringer T, Brown J, Crowder S Cancers (Basel). 2024; 16(13).

PMID: 39001427 PMC: 11240731. DOI: 10.3390/cancers16132364.

The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review.

Morimoto K, Yamada T, Takayama K Transl Lung Cancer Res. 2023; 12(11):2310-2321.

PMID: 38090528 PMC: 10713257. DOI: 10.21037/tlcr-23-581.

References

McGovern J, Dolan R, Skipworth R, Laird B, McMillan D . Cancer cachexia: a nutritional or a systemic inflammatory syndrome?. Br J Cancer. 2022; 127(3):379-382. PMC: 9073809. DOI: 10.1038/s41416-022-01826-2. View

Maccio A, Sanna E, Neri M, Oppi S, Madeddu C . Cachexia as Evidence of the Mechanisms of Resistance and Tolerance during the Evolution of Cancer Disease. Int J Mol Sci. 2021; 22(6). PMC: 8001015. DOI: 10.3390/ijms22062890. View

Maccio A, Lai P, Santona M, Pagliara L, Melis G, Mantovani G . High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998; 69(3):248-52. DOI: 10.1006/gyno.1998.4974. View

Mantovani G, Maccio A, Mura L, Massa E, Mudu M, Mulas C . Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med (Berl). 2001; 78(10):554-61. DOI: 10.1007/s001090000137. View

Mantovani G, Maccio A, Lai P, Massa E, Massa D, Mulas C . Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer. J Immunother. 2000; 23(2):267-74. DOI: 10.1097/00002371-200003000-00011. View

Sanna E, Tanca L, Cherchi C, Gramignano G, Oppi S, Chiai M . Decrease in Neutrophil-to-Lymphocyte Ratio during Neoadjuvant Chemotherapy as a Predictive and Prognostic Marker in Advanced Ovarian Cancer. Diagnostics (Basel). 2021; 11(7). PMC: 8303238. DOI: 10.3390/diagnostics11071298. View

Maccio A, Madeddu C, Massa D, Astara G, Farci D, Melis G . Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. J Cell Mol Med. 2008; 13(9B):3951-9. PMC: 4516542. DOI: 10.1111/j.1582-4934.2008.00408.x. View

Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E . A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol. 2011; 124(3):417-25. DOI: 10.1016/j.ygyno.2011.12.435. View

Maccio A, Oppi S, Madeddu C . COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?. J Ovarian Res. 2021; 14(1):28. PMC: 7868172. DOI: 10.1186/s13048-021-00772-6. View

10.

Maccio A, Madeddu C . Blocking inflammation to improve immunotherapy of advanced cancer. Immunology. 2019; 159(4):357-364. PMC: 7078000. DOI: 10.1111/imm.13164. View